Literature DB >> 10554017

Lack of involvement of ataxia telangiectasia mutated (ATM) in regulation of nuclear factor-kappaB (NF-kappaB) in human diploid fibroblasts.

B P Ashburner1, R E Shackelford, A S Baldwin, R S Paules.   

Abstract

It has been suggested that the cellular response to exposure to ionizing radiation involves activation of the transcription factor nuclear factor-kappaB (NF-kappaB) and that this response is defective in cells from individuals with ataxia telangiectasia (AT). In one study, it was found that SV40 large T-transformed cells derived from a patient null for the AT mutated (ATM) gene exhibited constitutive activation of NF-kappaB and that in those cells, inhibition of NF-kappaB by expression of a modified form of IkappaBalpha led to correction of the radiosensitivity associated with the AT phenotype [M. Jung et al., Science (Washington DC), 268: 1691-1621, 1995]. From those data, it was suggested that NF-kappaB played a role in the AT phenotype. We show here that normal diploid cells derived from AT patients do not exhibit constitutive activation of NF-kappaB. Furthermore, we provide data that the transformation process associated with SV40 large T antigen expression in AT-/- cells leads to aberrant cellular responses. Our studies highlight the importance of using diploid, nontransformed AT-/- cells for in vitro studies relevant to the AT phenotype whenever possible.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10554017

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  New insights into the role of nuclear factor-kappaB in cell growth regulation.

Authors:  F Chen; V Castranova; X Shi
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

Review 2.  Nuclear initiated NF-κB signaling: NEMO and ATM take center stage.

Authors:  Shigeki Miyamoto
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

3.  The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression.

Authors:  B P Ashburner; S D Westerheide; A S Baldwin
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

Review 4.  ATM-NF-kappaB connection as a target for tumor radiosensitization.

Authors:  Kazi Mokim Ahmed; Jian Jian Li
Journal:  Curr Cancer Drug Targets       Date:  2007-06       Impact factor: 3.428

Review 5.  NF-kappa B-mediated adaptive resistance to ionizing radiation.

Authors:  Kazi Mokim Ahmed; Jian Jian Li
Journal:  Free Radic Biol Med       Date:  2007-10-10       Impact factor: 7.376

6.  Imaging of nuclear factor κB activation induced by ionizing radiation in human embryonic kidney (HEK) cells.

Authors:  Arif Ali Chishti; Christa Baumstark-Khan; Christine E Hellweg; Günther Reitz
Journal:  Radiat Environ Biophys       Date:  2014-06-01       Impact factor: 1.925

7.  The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway.

Authors:  Prashanthi Javvadi; Andrew T Segan; Stephen W Tuttle; Constantinos Koumenis
Journal:  Mol Pharmacol       Date:  2008-02-05       Impact factor: 4.436

8.  A novel role for ATM in regulating proteasome-mediated protein degradation through suppression of the ISG15 conjugation pathway.

Authors:  Laurence M Wood; Surendran Sankar; Ryan E Reed; Arthur L Haas; Leroy F Liu; Peter McKinnon; Shyamal D Desai
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

Review 9.  The Role of Caspase-2 in Regulating Cell Fate.

Authors:  Vasanthy Vigneswara; Zubair Ahmed
Journal:  Cells       Date:  2020-05-19       Impact factor: 6.600

Review 10.  Evidence for the Involvement of the Master Transcription Factor NF-κB in Cancer Initiation and Progression.

Authors:  Yu Rou Puar; Muthu K Shanmugam; Lu Fan; Frank Arfuso; Gautam Sethi; Vinay Tergaonkar
Journal:  Biomedicines       Date:  2018-07-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.